Iron chelation therapy and its influence on the alleviation of EPO resistance in MDS patients.
10.7534/j.issn.1009-2137.2014.04.026
- Author:
Yao ZHANG
1
;
Chao XIAO
1
;
Shu-Cheng GU
1
;
Chun-Kang CHANG
2
Author Information
1. Department of Hematology, Shanghai Jiaotong University Sixth People's Hospital, Shanghai 200233, China.
2. Department of Hematology, Shanghai Jiaotong University Sixth People's Hospital, Shanghai 200233, China. E-mail: changchunkang7010@yahoo.cn.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
C-Reactive Protein;
metabolism;
Case-Control Studies;
Chelation Therapy;
Erythropoietin;
blood;
Female;
Ferritins;
blood;
Hemoglobins;
metabolism;
Humans;
Iron;
metabolism;
Iron Overload;
Male;
Middle Aged;
Myelodysplastic Syndromes;
drug therapy;
metabolism;
Recombinant Proteins;
therapeutic use
- From:
Journal of Experimental Hematology
2014;22(4):1027-1032
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the changes of erythropoietin (EPO), hemoglobin(Hb) and recombinant EPO (rEPO) levels in MDS patients receiving iron chelation therapy, and to explore the relationship between EPO and serum ferritin(SF). A total of 172 MDS patients and 30 healthy controls were studied. The levels of SF, EPO, serum iron (SI), total iron binding capacity (TIBC), C-reaction protein (CRP) and Hb were measured respectively, the level of SF was adjusted according to the changes of CRP. Among them, there were 34 cases of low-risk (SF>1 000 mg/L) receiving deferoxamine therapy, whose changes of SF, EPO, SI, TIBC, Hb levels were detected and compared before and after treatment. Besides, the difference in the incidence of EPO resistance in iron overload group and non-iron overload group was assessed before and after therapy, and 58 cases of low-risk and EPO<1 000 U/L MDS patients were given rEPO therapy. The results showed that the level of EPO in non-iron overload group was higher than that in the normal control group (997.44 ± 473.48 vs 467.27 ± 238.49, P < 0.05). Obviously, the level of EPO in iron overload group was higher than that in non-iron overload group and control group (3257.59 ± 697.19 vs 997.44 ± 473.48, P = 0.012, 3257.59 ± 697.19 vs 467.27 ± 238.49, P = 0.002). Otherwise, the incidence of EPO resistance in iron overload group was higher than that in non-iron overload group (18/35 vs 2/23, P = 0.001), and the level of EPO and SF was positively related to each other in iron overload group (r = 0.310,P = 0.036). After receiving iron chelation therapy, the levels of SF, SI, TIBC and EPO in iron overload group were significantly lower than that before therapy (3942.38 ± 641.82 vs 2266.35 ± 367.31, P = 0.028;48.61 ± 10.65 vs 28.52 ± 12.61, P = 0.034;59.84 ± 12.62 vs 33.76 ± 15.43, P = 0.045;3808.01 ± 750.22 vs 1954.78 ± 473.18, P = 0.042). Moreover, the level of Hb increased (35 ± 18 vs 57 ± 21, P = 0.046) and the EPO resistance in some patients was decreased. It is concluded that iron chelation therapy can improve the efficacy of EPO to alleviate EPO resistance in patients wtih anemic MDS, decrease the pathological level of EPO, enhance Hb levels and reduce the dependency on blood transfusion.
